110 related articles for article (PubMed ID: 10604750)
21. Ezrin immunoreactivity is associated with increasing malignancy of astrocytic tumors but is absent in oligodendrogliomas.
Geiger KD; Stoldt P; Schlote W; Derouiche A
Am J Pathol; 2000 Dec; 157(6):1785-93. PubMed ID: 11106550
[TBL] [Abstract][Full Text] [Related]
22. Analysis of autoantibodies to glycolipids on thymocytes in New Zealand black mice.
Ishii N; Watanabe K
Immunology; 1989 Oct; 68(2):215-20. PubMed ID: 2807379
[TBL] [Abstract][Full Text] [Related]
23. Gangliosides and neutral glycolipids in ependymal, neuronal and primitive neuroectodermal tumors.
Yates AJ; Franklin TK; McKinney P; Collins R; Comas T; Boesel CP; Pearl DK
J Mol Neurosci; 1999 Apr; 12(2):111-21. PubMed ID: 10527455
[TBL] [Abstract][Full Text] [Related]
24. Could changes in the regulation of the PI3K/PKB/Akt signaling pathway and cell cycle be involved in astrocytic tumor pathogenesis and progression?
Hlobilkova A; Ehrmann J; Sedlakova E; Krejci V; Knizetova P; Fiuraskova M; Kala M; Kalita O; Kolar Z
Neoplasma; 2007; 54(4):334-41. PubMed ID: 17822324
[TBL] [Abstract][Full Text] [Related]
25. Molecular genetic evidence for subtypes of oligoastrocytomas.
Maintz D; Fiedler K; Koopmann J; Rollbrocker B; Nechev S; Lenartz D; Stangl AP; Louis DN; Schramm J; Wiestler OD; von Deimling A
J Neuropathol Exp Neurol; 1997 Oct; 56(10):1098-104. PubMed ID: 9329453
[TBL] [Abstract][Full Text] [Related]
26. Mutation-specific IDH1 antibody differentiates oligodendrogliomas and oligoastrocytomas from other brain tumors with oligodendroglioma-like morphology.
Capper D; Reuss D; Schittenhelm J; Hartmann C; Bremer J; Sahm F; Harter PN; Jeibmann A; von Deimling A
Acta Neuropathol; 2011 Feb; 121(2):241-52. PubMed ID: 21069360
[TBL] [Abstract][Full Text] [Related]
27. Expression of oligodendroglial and astrocytic lineage markers in diffuse gliomas: use of YKL-40, ApoE, ASCL1, and NKX2-2.
Rousseau A; Nutt CL; Betensky RA; Iafrate AJ; Han M; Ligon KL; Rowitch DH; Louis DN
J Neuropathol Exp Neurol; 2006 Dec; 65(12):1149-56. PubMed ID: 17146289
[TBL] [Abstract][Full Text] [Related]
28. Nogo-a expression in glial CNS tumors: a tool to differentiate between oligodendrogliomas and other gliomas?
Kuhlmann T; Gutenberg A; Schulten HJ; Paulus W; Rohde V; Bruck W
Am J Surg Pathol; 2008 Oct; 32(10):1444-53. PubMed ID: 18685489
[TBL] [Abstract][Full Text] [Related]
29. Ceramide levels are inversely associated with malignant progression of human glial tumors.
Riboni L; Campanella R; Bassi R; Villani R; Gaini SM; Martinelli-Boneschi F; Viani P; Tettamanti G
Glia; 2002 Aug; 39(2):105-13. PubMed ID: 12112362
[TBL] [Abstract][Full Text] [Related]
30. Assessment of 1p/19q status by fluorescence in situ hybridization assay: A comparative study in oligodendroglial, mixed oligoastrocytic and astrocytic tumors.
Shukla B; Agarwal S; Suri V; Pathak P; Sharma MC; Gupta D; Sharma BS; Suri A; Halder A; Sarkar C
Neurol India; 2009; 57(5):559-66. PubMed ID: 19934553
[TBL] [Abstract][Full Text] [Related]
31. Sex- and age-related differences in ceramide dihexosides of primary human brain tumors.
Yates AJ; Franklin TK; Scheithauer BW; Burger PC; Pearl DK
Lipids; 1999 Jan; 34(1):1-4. PubMed ID: 10188590
[TBL] [Abstract][Full Text] [Related]
32. Contributions of biological tumor parameters to the incorporation rate of L: -[methyl-(11)C] methionine into astrocytomas and oligodendrogliomas.
Nojiri T; Nariai T; Aoyagi M; Senda M; Ishii K; Ishiwata K; Ohno K
J Neurooncol; 2009 Jun; 93(2):233-41. PubMed ID: 19099197
[TBL] [Abstract][Full Text] [Related]
33. Myelin basic protein (MBP) in human gliomas: a study of twenty-five cases.
Figols J; Iglesias-Rozas JR; Kazner E
Clin Neuropathol; 1985; 4(3):116-20. PubMed ID: 2410174
[TBL] [Abstract][Full Text] [Related]
34. Clinical utility of fluorescence in situ hybridization (FISH) in morphologically ambiguous gliomas with hybrid oligodendroglial/astrocytic features.
Fuller CE; Schmidt RE; Roth KA; Burger PC; Scheithauer BW; Banerjee R; Trinkaus K; Lytle R; Perry A
J Neuropathol Exp Neurol; 2003 Nov; 62(11):1118-28. PubMed ID: 14656070
[TBL] [Abstract][Full Text] [Related]
35. Differential expression between pilocytic and anaplastic astrocytomas: identification of apolipoprotein D as a marker for low-grade, non-infiltrating primary CNS neoplasms.
Hunter S; Young A; Olson J; Brat DJ; Bowers G; Wilcox JN; Jaye D; Mendrinos S; Neish A
J Neuropathol Exp Neurol; 2002 Mar; 61(3):275-81. PubMed ID: 11895042
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of invasiveness of astrocytoma using 1H-magnetic resonance spectroscopy: correlation with expression of matrix metalloproteinase-2.
Zhang K; Li C; Liu Y; Li L; Ma X; Meng X; Feng D
Neuroradiology; 2007 Nov; 49(11):913-9. PubMed ID: 17763847
[TBL] [Abstract][Full Text] [Related]
37. Loss of the AP-2alpha transcription factor is associated with the grade of human gliomas.
Heimberger AB; McGary EC; Suki D; Ruiz M; Wang H; Fuller GN; Bar-Eli M
Clin Cancer Res; 2005 Jan; 11(1):267-72. PubMed ID: 15671555
[TBL] [Abstract][Full Text] [Related]
38. CIC and FUBP1 mutations in oligodendrogliomas, oligoastrocytomas and astrocytomas.
Sahm F; Koelsche C; Meyer J; Pusch S; Lindenberg K; Mueller W; Herold-Mende C; von Deimling A; Hartmann C
Acta Neuropathol; 2012 Jun; 123(6):853-60. PubMed ID: 22588899
[TBL] [Abstract][Full Text] [Related]
39. Clarifying the diffuse gliomas: an update on the morphologic features and markers that discriminate oligodendroglioma from astrocytoma.
Gupta M; Djalilvand A; Brat DJ
Am J Clin Pathol; 2005 Nov; 124(5):755-68. PubMed ID: 16203285
[TBL] [Abstract][Full Text] [Related]
40. Expression of vascular endothelial growth factor in tumors and plasma from dogs with primary intracranial neoplasms.
Rossmeisl JH; Duncan RB; Huckle WR; Troy GC
Am J Vet Res; 2007 Nov; 68(11):1239-45. PubMed ID: 17975980
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
